Andrew Gengos - 22 Feb 2022 Form 4 Insider Report for Cyteir Therapeutics, Inc.

Role
Chief Business Officer
Signature
/s/ Andrew Gengos
Issuer symbol
N/A
Transactions as of
22 Feb 2022
Net transactions value
$0
Form type
4
Filing time
24 Feb 2022, 15:57:18 UTC
Previous filing
17 Jun 2021
Next filing
22 May 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CYT Stock Option (Right to Buy) Award $0 +35,000 $0.000000 35,000 22 Feb 2022 Common Stock 35,000 $5.96 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares of common stock underlying this stock option award vest as to 2.083% in 48 equal monthly installments, subject to the Reporting Person's continued employment with the Company through the applicable vesting date.